T
Thomas Langer
Researcher at Max Planck Society
Publications - 253
Citations - 26029
Thomas Langer is an academic researcher from Max Planck Society. The author has contributed to research in topics: Mitochondrion & mitochondrial fusion. The author has an hindex of 82, co-authored 222 publications receiving 23219 citations. Previous affiliations of Thomas Langer include Heidelberg University & Ludwig Maximilian University of Munich.
Papers
More filters
Journal ArticleDOI
Preparation of Chiral Phosphorus, Sulfur and Selenium Containing 2- Aryloxazolines.
M. Peer,J. C. De Jong,Matthias Kiefer,Thomas Langer,Heiko Rieck,H. Schell,Peter Sennhenn,Jürgen Sprinz,Henning Steinhagen,Burkhard Wiese,Günter Helmchen +10 more
Journal ArticleDOI
Counter-contestation in global health governance: The WHO and its member states in emergency settings.
TL;DR: The authors analyzes the evolution of global health governance by relating a principal-agent approach and contestation considerations and explores how and to what extent WHO actively engages in the political exchange of diplomatic moves and manoeuvres, creating contestation as a mutual game between states and International Organizations.
Posted ContentDOI
Metabolic rewiring of mitochondria in senescence revealed by time-resolved analysis of the mitochondrial proteome
TL;DR: This study investigated the rewiring of mitochondria upon development of the senescent state in human IMR90 fibroblasts and revealed extensive reprogramming of the mitochondrial proteome upon senescence development and the identification of metabolic pathways that are rewired with different kinetics upon establishment of thesenescent state.
Journal ArticleDOI
Catalytic Asymmetric Hydrosilylation of Ketones Using Rhodium‐(I)‐ Complexes of Chiral Phosphinooxazoline Ligands.
Patent
Protéines de fusion pour traiter un syndrome métabolique
Oliver Boscheinen,Matthias Dreyer,Habermann Paul,Hans-Ludwig Schaefer,Mark Sommerfeld,Thomas Langer +5 more
TL;DR: In this article, a proteine de fusion comprenant au moins un compose FGF-21 (facteur 21 de croissance fibroblastique) and an agoniste of GLP-1R (recepteur du peptide 1 de type glucagon), ainsi que des compositions pharmaceutiques, des utilisations medicales and des methodes de traitement impliquant la proteine of fusion, en particulier dans le domaine du diabete, de la dyslipidemie, de l'obesite